News for Monopar Therapeutics Inc (1IY.MU)

Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery - Initial focus on use in bladder cancer surgery GlobeNewswire March 02, 2021 WILMETTE, Ill., March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused...

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on ...

Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC) There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM GlobeNewswire February 16, 2021 WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics...

Day trading is never easy. It takes a level of consistency and resolve to do well over an extended period of time and those attributes require practice and ...

Today's Daily Dose brings you news about encouraging data related to AC Immune's vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease; ESSA Pharma's prostate cancer trial results; GenMark's near-term catalyst; Infinity's urothelial cancer trial data; and Monopar's imaging agent to Improve surgical outcomes in bladder cancer.

Toward the end of trading Thursday, the Dow traded down 0.40% to 31,312.17 while the NASDAQ fell 0.04% to 13,966.26. The S&P also lost 0.22% to ...

Shares of Monopar Therapeutics Inc. (MNPR) are up more than 60% Thursday morning The company announced publication of a peer-reviewed study showing the potential utility of MNPR-101, the company's proprietary humanized uPAR antibody, as a uPAR imaging agent to improve surgical outcomes in bladder cancer.

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer GlobeNewswire February 11, 2021 WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the...

Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada GlobeNewswire February 09, 2021 WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients,...